JP2023532046A - 組換え修飾線維芽細胞増殖因子およびそれを使用した治療 - Google Patents

組換え修飾線維芽細胞増殖因子およびそれを使用した治療 Download PDF

Info

Publication number
JP2023532046A
JP2023532046A JP2022580315A JP2022580315A JP2023532046A JP 2023532046 A JP2023532046 A JP 2023532046A JP 2022580315 A JP2022580315 A JP 2022580315A JP 2022580315 A JP2022580315 A JP 2022580315A JP 2023532046 A JP2023532046 A JP 2023532046A
Authority
JP
Japan
Prior art keywords
polypeptide
modified fgf
seq
fgf
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532046A5 (https=
JPWO2021263134A5 (https=
Inventor
エヴェレス，デイヴィッド
Original Assignee
トレフォイル セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トレフォイル セラピューティクス，インク． filed Critical トレフォイル セラピューティクス，インク．
Publication of JP2023532046A publication Critical patent/JP2023532046A/ja
Publication of JP2023532046A5 publication Critical patent/JP2023532046A5/ja
Publication of JPWO2021263134A5 publication Critical patent/JPWO2021263134A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022580315A 2020-06-26 2021-06-25 組換え修飾線維芽細胞増殖因子およびそれを使用した治療 Pending JP2023532046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044980P 2020-06-26 2020-06-26
US63/044,980 2020-06-26
PCT/US2021/039139 WO2021263134A1 (en) 2020-06-26 2021-06-25 Recombinant modified fibroblast growth factors and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
JP2023532046A true JP2023532046A (ja) 2023-07-26
JP2023532046A5 JP2023532046A5 (https=) 2024-07-02
JPWO2021263134A5 JPWO2021263134A5 (https=) 2024-07-02

Family

ID=79281929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580315A Pending JP2023532046A (ja) 2020-06-26 2021-06-25 組換え修飾線維芽細胞増殖因子およびそれを使用した治療

Country Status (6)

Country Link
US (1) US20240024421A1 (https=)
EP (1) EP4172351A4 (https=)
JP (1) JP2023532046A (https=)
KR (1) KR20230066318A (https=)
CN (1) CN116710568A (https=)
WO (1) WO2021263134A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4621067A3 (en) 2017-05-05 2025-11-19 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
TWI865835B (zh) * 2020-11-16 2024-12-11 雅祥生技醫藥股份有限公司 穩定的酸性纖維母細胞生長因子組合物
US20230022990A1 (en) * 2021-05-14 2023-01-26 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease
WO2023019218A1 (en) * 2021-08-12 2023-02-16 Trefoil Therapeutics, Inc. Modified fibroblast growth factors for treating fibrotic diseases
AU2024247068A1 (en) * 2023-03-28 2025-10-16 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN116392441B (zh) * 2023-04-21 2023-11-28 上海腾瑞制药股份有限公司 一种酸性成纤维细胞生长因子滴眼液制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009534390A (ja) * 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
JP2019510078A (ja) * 2016-02-23 2019-04-11 セセン バイオ， インコーポレイテッド Ｉｌ−６アンタゴニスト製剤およびその使用
US20200157164A1 (en) * 2017-06-23 2020-05-21 Zhuhai Essex Bio-Pharmaceutical Co., Ltd. RECOMBINANT HUMAN-BASIC FIBROBLAST GROWTH FACTOR (rh-bFGF) AND PHARMACEUTICAL COMPOSITION COMPRISING rh-bFGF
JP2020518287A (ja) * 2017-05-05 2020-06-25 トレフォイル セラピューティクス，インク． 組み換え修飾された繊維芽細胞成長因子及びその治療用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022758A (en) * 1973-06-19 1977-05-10 Ab Kabi Isolation of coagulation factors I and VIII from biological material
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US20050227929A1 (en) 2003-11-13 2005-10-13 Masferrer Jaime L Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
US7790682B1 (en) 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
US20080125580A1 (en) * 2006-07-14 2008-05-29 Genentech, Inc. Refolding of Recombinant Proteins
ES2516694T3 (es) * 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
US7696171B1 (en) 2006-11-09 2010-04-13 The Florida State University Research Foundation, Inc. Mutant polypeptides of fibroblast growth factor 1
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110224404A1 (en) 2010-03-11 2011-09-15 Florida State University Research Foundation Method for development of a peptide building block useful for de novo protein design
CA2796459C (en) * 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
US9714291B2 (en) * 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
US11103552B2 (en) * 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009534390A (ja) * 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
JP2019510078A (ja) * 2016-02-23 2019-04-11 セセン バイオ， インコーポレイテッド Ｉｌ−６アンタゴニスト製剤およびその使用
JP2020518287A (ja) * 2017-05-05 2020-06-25 トレフォイル セラピューティクス，インク． 組み換え修飾された繊維芽細胞成長因子及びその治療用途
US20200157164A1 (en) * 2017-06-23 2020-05-21 Zhuhai Essex Bio-Pharmaceutical Co., Ltd. RECOMBINANT HUMAN-BASIC FIBROBLAST GROWTH FACTOR (rh-bFGF) AND PHARMACEUTICAL COMPOSITION COMPRISING rh-bFGF

Also Published As

Publication number Publication date
US20240024421A1 (en) 2024-01-25
CN116710568A (zh) 2023-09-05
EP4172351A4 (en) 2024-08-14
EP4172351A1 (en) 2023-05-03
KR20230066318A (ko) 2023-05-15
WO2021263134A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
JP2023532046A (ja) 組換え修飾線維芽細胞増殖因子およびそれを使用した治療
US12600756B2 (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
US20250066440A1 (en) Methods of treatment using modified fgf-1 polypeptides
US20210338777A1 (en) Modified fibroblast growth factors for the treatment of ocular disorders
JP7558260B2 (ja) 眼科障害の処置または防止における使用のための薬剤
CN110945123B (zh) 生产可溶性重组人碱性成纤维细胞生长因子(rh-bFGF)的方法
WO2023019218A1 (en) Modified fibroblast growth factors for treating fibrotic diseases
US20220168434A1 (en) Application of transthyretin in entering eye and preparing drop
RU2811435C2 (ru) Рекомбинантные модифицированные факторы роста фибробластов и их терапевтическое применение
CN115942951A (zh) Ngf变体，制备，组合物和治疗用途
HK40072504A (en) Agent for use in treatment or prevention of ophthalmic disorders
HK40019822B (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
HK40019822A (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN117209589A (zh) 一种重组载脂蛋白j、制备方法及应用
WO2012122859A1 (zh) 人角质细胞生长因子-ⅰ二硫键变构体及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260204